Advertisement

Drugs & Therapy Perspectives

, Volume 10, Issue 3, pp 10–13 | Cite as

Early intravenous to oral switch therapy in community-acquired pneumonia is advantageous

New Drugs and Disease Management

Keywords

Adis International Limited Ceftriaxone Cefoperazone Cefixime Cefpodoxime 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gillum B. Trends in hospital utilization: United States 1988–92. National Center for Health Statistics: Hyattsville, Md, 1996; (Vital and Health Statistics Series 13: no 124.) Available from: URL: http://www.cdc.gov.nchswww/data/sr13_124.pdf [Accessed 97/04/17]Google Scholar
  2. 2.
    Elixhauser A, McCarthy E. Clinical classifications for health policy research, version 2: hospital inpatient statistics. [Monograph online]. Agency for Health Care Policy and Research: Rockville, Md, 1996; AHCPR Publication No. 96-0017. Available from: URL: http://www.access.gpo.gov/ahcpr/hcuprnl.html [Accessed 97/04/17]Google Scholar
  3. 3.
    American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418–26Google Scholar
  4. 4.
    British Thoracic Society. Guidelines for the management of community acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346–50Google Scholar
  5. 5.
    Marrie TH. Community-acquired pneumonia. Clin Infect Dis 1994; 18: 501–15PubMedCrossRefGoogle Scholar
  6. 6.
    Fine MJ, Medsger AR, Stone RA, et al. The hospital discharge decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team Cohort Study. Arch Intern Med 1997; 157: 47–56PubMedCrossRefGoogle Scholar
  7. 7.
    Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273–6PubMedCrossRefGoogle Scholar
  8. 8.
    Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 1995; 29: 561–5PubMedGoogle Scholar
  9. 9.
    Elliott M. Oral ceftibuten as step-down therapy after parenteral 3rd-generation cephalosporin treatment for serious infection. [Abstract] Can J Infect Dis 1995; 6 (Suppl. C): 242CGoogle Scholar
  10. 10.
    Ehrenkranz NJ, Nerenberg DE, Shultz JM, et al. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay. Infect Control Hosp Epidemiol 1992; 13: 21–32PubMedCrossRefGoogle Scholar
  11. 11.
    Gentry LO, Rodriguez-Gomez G, Kohler RB, et al. Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. Am Rev Respir Dis 1992; 145: 31–5PubMedCrossRefGoogle Scholar
  12. 12.
    Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991; 91: 462–70PubMedCrossRefGoogle Scholar
  13. 13.
    Quintiliani R, Nightingale CH, Crowe HM, et al. Strategic antibiotic decision-making at the formulary level. Rev Infect Dis 1991; 13 (Suppl. 9): S770–7PubMedCrossRefGoogle Scholar
  14. 14.
    Guay DRP. Sequential antimicrobial therapy. A realistic approach to cost containment? PharmacoEconomics 1993; 3: 341–4PubMedCrossRefGoogle Scholar
  15. 15.
    Jewesson PJ. Economic impact of intravenous-to-oral antibacterial stepdown therapy. Clinical Drug Investigations 1996; 11 (Suppl. 2): 1–9CrossRefGoogle Scholar
  16. 16.
    Jewesson P. Cost-effectiveness and value of an IV switch. PharmacoEconomics 1994; 5 (Suppl. 2): 20–6PubMedCrossRefGoogle Scholar
  17. 17.
    Ramirez JA. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis 1995; 22: 219–23PubMedCrossRefGoogle Scholar
  18. 18.
    Quintiliani R, Crowe HM, Nightingale C. Transitional antibiotic therapy. Can J Infect Dis 1995; 6 (Suppl. A): 6A–10AGoogle Scholar
  19. 19.
    Grasela TH, Welage LS, Walawander CA, et al. A nationwide survey of antibiotic prescribing patterns and clinical outcomes in patients with bacterial pneumonia. DICP, Ann Pharmacother 1990; 24: 1220–5Google Scholar
  20. 20.
    Saltiel E, Weingarten S. Drug treatment of pneumonia in the elderly. PharmacoEconomics 1993; 3: 268–75PubMedCrossRefGoogle Scholar
  21. 21.
    Mandell LA. Community-acquired pneumonia. Etiology, epidemiology, and treatment. Chest 1995; 108 (Suppl.): 35S–42SPubMedCrossRefGoogle Scholar
  22. 22.
    Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1618–24PubMedCrossRefGoogle Scholar
  23. 23.
    Rains CP, Bryson HM, Peters DH. Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1995; 49: 577–617PubMedCrossRefGoogle Scholar
  24. 24.
    Brogden RN, Ward A. Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration. Drugs 1988; 35: 604–45PubMedCrossRefGoogle Scholar
  25. 25.
    Brogden RN, Campoli-Richards DM. Cefixime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1989; 38: 524–50PubMedCrossRefGoogle Scholar
  26. 26.
    Frampton JE, Brogden RN, Langtry HD, et al. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44: 889–917PubMedCrossRefGoogle Scholar
  27. 27.
    Wiseman LR, Balfour JA. Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1994; 47: 784–808PubMedCrossRefGoogle Scholar
  28. 28.
    Ramirez JA, Ahkee S. Cost savings resulting from early switch therapy to oral cefixime in the treatment of hospitalized patients with community-acquired pneumonia. [Abstract] Clin Infect Dis 1995; 21: 741Google Scholar
  29. 29.
    Janknegt R, van der Meer JWM. Sequential therapy with intravenous and oral cephalosporins. J Antimicrob Chemother 1994 Jan; 33: 169–77PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Personalised recommendations